Bae JuneSung, Choi Yun Sik, Cho Gunsik, Jang Se Jin
Department of Research and Development, OncoClew Co., Ltd., Seoul 04778, Korea.
Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.
Cancers (Basel). 2022 Apr 25;14(9):2144. doi: 10.3390/cancers14092144.
The cancer burden is rapidly increasing in most countries, and thus, new anticancer drugs for effective cancer therapy must be developed. Cancer model systems that recapitulate the biological processes of human cancers are one of the cores of the drug development process. PDCO has emerged as a unique model that preserves the genetic, physiological, and histologic characteristics of original cancer, including inter- and intratumoral heterogeneities. Due to these advantages, the PCDO model is increasingly investigated for anticancer drug screening and efficacy testing, preclinical patient stratification, and precision medicine for selecting the most effective anticancer therapy for patients. Here, we review the prospects and limitations of PDCO compared to the conventional cancer models. With advances in culture success rates, co-culture systems with the tumor microenvironment, organoid-on-a-chip technology, and automation technology, PDCO will become the most promising model to develop anticancer drugs and precision medicine.
在大多数国家，癌症负担正在迅速增加，因此，必须开发用于有效癌症治疗的新型抗癌药物。能够概括人类癌症生物学过程的癌症模型系统是药物开发过程的核心之一。人源肿瘤细胞系衍生的类器官（PDCO）已成为一种独特的模型，它保留了原始癌症的遗传、生理和组织学特征，包括肿瘤间和肿瘤内的异质性。由于这些优势，越来越多的研究将PCDO模型用于抗癌药物筛选和疗效测试、临床前患者分层以及为患者选择最有效的抗癌治疗的精准医学。在这里，我们综述了与传统癌症模型相比，PDCO的前景和局限性。随着培养成功率、与肿瘤微环境的共培养系统、芯片上类器官技术和自动化技术的进步，PDCO将成为开发抗癌药物和精准医学最有前景的模型。
